Sign In
Buy ARGX
$844.50
+13.71 (+1.65%)
At Close: Aug 04, 2026
argenx: Next Phase Of Growth With Efgartigimod And ARGX-117
12:36pm, Wednesday, 30'th Jun 2021
One of argenx's main competitors, Immunovant, suffered clinical setbacks this year and these setbacks have further solidified efgartigimod's potential best-in-class position. argenx to become a commer
Results from ADAPT showed treatment with efgartigimod provided clinically meaningful improvement s in strength and quality of life measures in g eneralized m yasthenia g ravis (gMG )
Argenx Is a Biotech Stock With Big Potential
08:17am, Tuesday, 15'th Jun 2021
The company's main selling point is a drug called efgartigimod, which the company is testing in six different diseases.
argenx (ARGX) to Regain AML Candidate After J&J's Dismissal
12:02pm, Tuesday, 08'th Jun 2021
argenx (ARGX) is developing cusatuzumab as potential treatment for acute myeloid leukemia. However, its partner, J&J, decided to discontinue the development agreement with the company for the candidat
Argenx Regains Global Rights from Johnson & Johnson to Blood Cancer Candidate Cusatuzumab
08:31am, Monday, 07'th Jun 2021
Johnson & Johnson (NYSE: JNJ) has walked away from a $1.6 billion blood cancer candidate deal with Argenx SE (NASDAQ: ARGX) for the CD70-targeting cusatuzumab. The pair first came together to dev
argenx to regain global rights to cusatuzumab
01:00am, Monday, 07'th Jun 2021
Regulated Information/Inside Information
argenx Appoints Karl Gubitz as Chief Financial Officer
04:01am, Tuesday, 01'st Jun 2021
June 1, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, t
argenx to Present at Upcoming Investor Conferences
01:00am, Tuesday, 01'st Jun 2021
June 1, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, t
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q1 2021 Results - Earnings Call Transcript
03:08pm, Friday, 14'th May 2021
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q1 2021 Results - Earnings Call Transcript
Recap: argenx Q1 Earnings
07:07am, Friday, 14'th May 2021
Shares of argenx (NASDAQ:ARGX) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 60.68% year over year to ($0.81), which may not compare to the esti
argenx Reports First Quarter 2021 Financial Results and Provides Business Update
01:00am, Friday, 14'th May 2021
Japanese Marketing Authorization Application (J-MAA) for efgartigimod accepted for review by Japan's Pharmaceuticals and Medical Device Agency (PMDA) for generalized myasthenia gravis (gMG)
argenx's Earnings Outlook
12:45pm, Thursday, 13'th May 2021
argenx (NASDAQ:ARGX) releases its next round of earnings this Friday, May 14. Here is Benzinga's essential guide to argenx's Q1 earnings report.
argenx announces results of Annual General Meeting of Shareholders
05:00am, Tuesday, 11'th May 2021
May 1 1 , 20 2 1 Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and ca
argenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 2021
01:00am, Friday, 07'th May 2021
May 7, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, to
argenx Management to Present at Upcoming Virtual Investor Conferences
01:00am, Wednesday, 28'th Apr 2021
April 28, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer,
